Ying Liu

Ying Liu focuses her practice on capital markets transactions and Hong Kong Listing Rules compliance of Hong Kong listed companies.

Ying is a native Mandarin speaker and is fluent in English.

Representative Matters:

IPO

• Advised YH Entertainment, the largest artist management company in China, on its HK$490 million IPO on HKEX 
• Advised TI Cloud, a cloud-native customer contact solution provider, on its HK$559.4 million (US$71.7 million) Hong Kong IPO
• Advised GOGOX, an online intracity logistics platform, on its HK$670.8 million Hong Kong IPO
• Advised Legend Biotech, a leading global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications and a subsidiary of GenScript Biotech Corporation (HK.1548), on its US$487 million IPO and spin-off listing on Nasdaq 
• Advised EHang on its US$40 million IPO on Nasdaq
• Advised Shenzhen Fangdd Network Technology on its US$78 million IPO on Nasdaq
• Advised BabyTree Group on its US$218 million Hong Kong IPO
• Advised CLSA Capital Markets Limited (the sole sponsor) and underwriters on the US$80 million Hong Kong IPO of China Chunlai Education Group Co., Ltd.
• Advised CSC Financial Co., Ltd. on its US$915 million Hong Kong IPO
• Advised Orient Securities Company Limited on its US$876 million Hong Kong IPO
• Advised Pa Shun Pharmaceutical International Holdings Limited on its US$39.2 million Hong Kong IPO
• Advised Investec Capital Asia Limited as the sole sponsor in the reverse takeover and deemed new listing of BeijingWest Industries International Limited

Compliance

• Advised CSC Financial Co., Ltd. (HKEX: 6066) on its post listing compliance
• Advised Mongolia Mining Corporation (HKEX: 975) on its post listing compliance

Others

• Advised CLSA Limited as the placing agent on the HK$393 million placing of existing shares and top-up subscription of new shares of China New Higher Education Group Limited